In the first half of next year the first patient will dosed with higher doses, there will be interim data from the combo trials, they will initiate a tumour archiving program and establish a US R&D facility.
For the second half, more interim data from those given higher doses, they will incorporate closed automation tech and start a trial in the follow-on indication.
As for the gene editing tech (undisclosed), it may be used to prevent the expression of immune checkpoints expressed, add molecules to increase trafficking to tumours, and/or deliver inflammatory mediators into the TME, including but not limited to cytokines, soluble immune-regulatory receptors and/or ligands.
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM